Examining immune cell function in breast cancer patients
Official title: Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Run by Ohio State University Comprehensive Cancer Center · NCT04022616 · Data updated 2026-11-12
This study looks at how certain immune cells work in people with breast cancer to see if it can help find better treatments in the future.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 99 (estimated) |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | June 4, 2010 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT04022616 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with stage I-III breast malignancy who can provide informed consent.
✕Probably not a fit
Patients who are unable to tolerate venipuncture will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on understanding the function of myeloid-derived suppressor cells in patients with breast cancer. It involves collecting specimens from participants to analyze the immune response related to their cancer. The study aims to gather insights that could inform future therapeutic strategies. Participants will be monitored to assess the characteristics and behavior of these immune cells in the context of breast cancer.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of immune responses in breast cancer, potentially leading to improved treatment strategies.
How similar studies have gone: While this specific approach is observational, similar studies investigating immune cell functions in cancer have shown promising results in understanding tumor biology.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Stage I-III breast malignancy Exclusion Criteria: * Unable to tolerate venipuncture
Where it's running
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: William Carson, MD — Ohio State Comprehensive Cancer Center
- Study coordinator: Ohio State Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 1-800-293-5066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.